These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 39043615)

  • 1. Biological use influences the impact of inflammation on risk of major adverse cardiovascular events in rheumatoid arthritis.
    Karpouzas GA; Ormseth SR; van Riel PLCM; Gonzalez-Gay MA; Corrales A; Rantapää-Dahlqvist S; Sfikakis PP; Dessein P; Tsang L; Hitchon C; El-Gabalawy H; Pascual-Ramos V; Contreras-Yáñez I; Colunga-Pedraza IJ; Galarza-Delgado DA; Azpiri-Lopez JR; Semb AG; Misra DP; Hauge EM; Kitas G
    RMD Open; 2024 Jul; 10(3):. PubMed ID: 39043615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Biological Disease-Modifying Antirheumatic Drugs and the Risk of Cardiovascular Events: A Systematic Review and Meta-Analysis.
    Hu S; Lin C; Cai X; Zhu X; Lv F; Nie L; Ji L
    Mediators Inflamm; 2021; 2021():7712587. PubMed ID: 34504395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of disease activity and treatment of comorbidities on the risk of myocardial infarction in rheumatoid arthritis.
    Meissner Y; Zink A; Kekow J; Rockwitz K; Liebhaber A; Zinke S; Gerhold K; Richter A; Listing J; Strangfeld A
    Arthritis Res Ther; 2016 Aug; 18(1):183. PubMed ID: 27495156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and risk factors of major cardiovascular events in rheumatoid arthritis and psoriatic arthritis: A population-based cohort study.
    Meng H; Lam SH; So H; Tam LS
    Semin Arthritis Rheum; 2024 Apr; 65():152416. PubMed ID: 38368730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.
    Genovese MC; Kalunian K; Gottenberg JE; Mozaffarian N; Bartok B; Matzkies F; Gao J; Guo Y; Tasset C; Sundy JS; de Vlam K; Walker D; Takeuchi T
    JAMA; 2019 Jul; 322(4):315-325. PubMed ID: 31334793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction Aided Tapering In rheumatoid arthritis patients treated with biOlogicals (PATIO): protocol for a randomized controlled trial.
    Messelink MA; van der Leeuw MS; den Broeder AA; Tekstra J; van der Goes MC; Heijstek MW; Lafeber F; Welsing PMJ
    Trials; 2022 Jun; 23(1):494. PubMed ID: 35710576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum cholesterol loading capacity on macrophages is linked to coronary atherosclerosis and cardiovascular event risk in rheumatoid arthritis.
    Karpouzas GA; Papotti B; Ormseth S; Palumbo M; Hernandez E; Adorni MP; Zimetti F; Budoff M; Ronda N
    RMD Open; 2022 Sep; 8(2):. PubMed ID: 36113961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative cardiovascular safety with janus kinase inhibitors and biological disease-modifying antirheumatic drugs as used in clinical practice: an observational cohort study from Sweden in patients with rheumatoid arthritis.
    Bower H; Frisell T; di Giuseppe D; Delcoigne B; Askling J
    RMD Open; 2023 Nov; 9(4):. PubMed ID: 37996125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study.
    Ogdie A; Yu Y; Haynes K; Love TJ; Maliha S; Jiang Y; Troxel AB; Hennessy S; Kimmel SE; Margolis DJ; Choi H; Mehta NN; Gelfand JM
    Ann Rheum Dis; 2015 Feb; 74(2):326-32. PubMed ID: 25351522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular risk estimation with 5 different algorithms before and after 5 years of bDMARD treatment in rheumatoid arthritis.
    Cacciapaglia F; Fornaro M; Venerito V; Perniola S; Urso L; Iannone F
    Eur J Clin Invest; 2020 Dec; 50(12):e13343. PubMed ID: 32654116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C-reactive protein and 10-year cardiovascular risk in rheumatoid arthritis.
    Erre GL; Cacciapaglia F; Sakellariou G; Manfredi A; Bartoloni E; Viapiana O; Fornaro M; Cauli A; Mangoni AA; Woodman RJ; Palermo BL; Gremese E; Cafaro G; Nucera V; Vacchi C; Spinelli FR; Atzeni F; Piga M;
    Eur J Intern Med; 2022 Oct; 104():49-54. PubMed ID: 35821191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential benefits of biologics on stroke and mortality in patients with rheumatoid arthritis: A nationwide population-based cohort study in Taiwan.
    Tang CH; Yu F; Huang CY; Chen DY
    Int J Rheum Dis; 2019 Aug; 22(8):1544-1552. PubMed ID: 31240863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of filgotinib in rheumatoid arthritis: a real-life multicentre experience.
    La Barbera L; Rizzo C; Camarda F; Atzeni F; Miceli G; Molica Colella AB; Franchina V; Giardina A; Corrao S; Provenzano G; Bursi R; Foti R; Dal Bosco Y; Debilio C; Luppino F; Colaci M; Aprile ML; Bentivegna M; Cassarà E; Lo Gullo A; De Andres MI; Guggino G
    Clin Exp Rheumatol; 2024 May; 42(5):991-998. PubMed ID: 38197190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydroxychloroquine use is associated with reduced mortality risk in older adults with rheumatoid arthritis.
    Iyer P; Gao Y; Jalal D; Girotra S; Singh N; Vaughan-Sarrazin M
    Clin Rheumatol; 2024 Jan; 43(1):87-94. PubMed ID: 37498463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cotreatment with methotrexate in routine care patients with rheumatoid arthritis receiving biological treatment yields better outcomes over time.
    Boone NW; Sepriano A; van der Kuy PH; Janknegt R; Peeters R; Landewé RBM
    RMD Open; 2019; 5(1):e000836. PubMed ID: 30740244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy.
    Rao VU; Pavlov A; Klearman M; Musselman D; Giles JT; Bathon JM; Sattar N; Lee JS
    Arthritis Rheumatol; 2015 Feb; 67(2):372-80. PubMed ID: 25332171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum Immunoglobulin G Levels to Porphyromonas gingivalis Peptidylarginine Deiminase Affect Clinical Response to Biological Disease-Modifying Antirheumatic Drug in Rheumatoid Arthritis.
    Kobayashi T; Ito S; Kobayashi D; Shimada A; Narita I; Murasawa A; Nakazono K; Yoshie H
    PLoS One; 2016; 11(4):e0154182. PubMed ID: 27111223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study.
    Buch MH; Bhatt DL; Charles-Schoeman C; Giles JT; Mikuls T; Koch GG; Ytterberg S; Nagy E; Jo H; Kwok K; Connell CA; Masri KR; Yndestad A
    RMD Open; 2024 Apr; 10(2):. PubMed ID: 38609322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological Disease-Modifying Antirheumatic Drugs and Osteoporotic Fracture Risk in Patients with Rheumatoid Arthritis: A Danish Cohort Study.
    Abtahi S; Cordtz R; Dreyer L; Driessen JHM; Boonen A; Burden AM
    Am J Med; 2022 Jul; 135(7):879-888.e3. PubMed ID: 35134369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register.
    Meissner Y; Schäfer M; Albrecht K; Kekow J; Zinke S; Tony HP; Strangfeld A
    RMD Open; 2023 Oct; 9(4):. PubMed ID: 37880180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.